Drug Trial Radar · NCT02740712
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Apr 2016
Primary completion
Mar 2017
Study completion Sep 2019
Sponsor
- Lead sponsor
- pharmaand GmbHIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.
Conditions
- Neoplasms
Interventions
CaffeineDrug
200 mg (4 x 50mg) Tablet
WarfarinDrug
10 mg (2 x 5mg) Tablet
OmeprazoleDrug
40 mg Tablet
MidazolamDrug
5 mg/mL
digoxinDrug
.25 mg Tablet
Vitamin KDrug
10 mg Tablet
RucaparibDrug
200 \& 300 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time dataTime frame: Days 1-5 and Days 12-16
- PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time dataTime frame: Days 1-5 and Days 12-16
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Med Polonia
Poznan, Poland
Zachodniopomorskie Centrum Onkologii Centrum Innowacji
Szczecin, Poland
BioVirtus Research Site
Kajetany, Mokra 7, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.